Core Viewpoint - Microchip Biotech (688321.SH) has received the acceptance notice for the clinical trial application of its self-developed drug, Siglitazone Metformin Sustained-Release Tablets, for the treatment of type 2 diabetes in adult patients from the National Medical Products Administration [1] Group 1 - The company and its wholly-owned subsidiary, Chengdu Microchip Pharmaceutical Co., Ltd., have recently received the acceptance notice for the clinical trial application [1] - The Siglitazone Metformin Sustained-Release Tablets are a fixed-dose combination formulation of Siglitazone and Metformin, developed by the company [1] - This drug aims to provide better blood glucose control for patients with type 2 diabetes through different mechanisms of action [1]

Core Viewpoint - Microchip Biotech (688321) has received acceptance for its clinical trial application for the combination drug of Siglecatin Sodium and Metformin Hydrochloride for treating adult patients with type 2 diabetes from the National Medical Products Administration [1] Group 1 - The company and its wholly-owned subsidiary Chengdu Microchip Pharmaceutical Co., Ltd. have recently received the acceptance notice for the clinical trial application [1] - The clinical trial application is for a self-developed drug, which is a combination of PPAR full agonist and Metformin [1] - Currently, there are no PPAR full agonist and Metformin combination formulations in clinical trial stages globally [1]

Core Viewpoint - The company and its wholly-owned subsidiary, Chengdu Microchip Pharmaceutical, have received a Notice of Acceptance from the National Medical Products Administration for the clinical trial application of its self-developed sustained-release formulation of Siglitazone Sodium and Metformin for the treatment of type 2 diabetes in adult patients, marking a significant step in its drug development pipeline [1] Group 1 - The clinical trial application was accepted on January 5, 2026 [1] - The drug is a fixed-dose combination sustained-release formulation of Siglitazone Sodium and Metformin, with no similar combination formulations currently in clinical trials globally [1] - The company can commence clinical trials if no negative or questioning opinions are received within 60 days from the acceptance date, although there is uncertainty regarding the ability to proceed [1]

Core Viewpoint - Microchip Biotech (688321.SH) has received a clinical trial acceptance notice from the National Medical Products Administration (NMPA) for its self-developed metformin sustained-release tablets, aimed at treating adult patients with type 2 diabetes [1] Group 1 - The company and its wholly-owned subsidiary Chengdu Microchip Pharmaceutical Co., Ltd. have successfully submitted a clinical trial application for the drug [1] - The acceptance of the clinical trial application marks a significant step in the development of the drug for type 2 diabetes treatment [1]